The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

A neuroblastoma patient treated with CAR T-cell therapy as a child achieved a complete response and remains in remission more than 18 years later. Researchers suggest this is the longest reported ...

Overall survival and complete response rates were comparable across a younger and an older cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). DLBCL is the most common ...

Please provide your email address to receive an email when new articles are posted on . Two first-in-class adoptive cell therapies show promise for patients with advanced melanoma or synovial sarcoma.

A recent study published in Nature Immunology demostrates that durable asthma remission can be achieved with engineered and long-lived chimeric antigen receptor (CAR) T-cell treatment in mice. Study: ...